Reneo Pharmaceuticals is a pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, to treat rare diseases such as fatty acid oxidation disorders and primary mitochondrial myopathies. The company merged with OnKure Therapeutics.